ArticleCureus2026
Fibromatosis-Like Metaplastic Triple-Negative Breast Cancer: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibromatosis-like metaplastic carcinoma (FLMC) is an extremely rare subtype of metaplastic breast carcinoma that closely resembles desmoid-type fibromatosis histologically, making it one of the most diagnostically challenging breast lesions. In contrast to most triple-negative breast cancers, FLMC follows a relatively indolent clinical course, though local recurrence is well documented, and because so few cases have been reported, no established treatment guidelines exist and the role of chemotherapy remains uncertain. We present the case of a 63-year-old woman recalled from routine screening digital breast tomosynthesis for an irregular, spiculated mass in the right breast, confirmed on biopsy to be FLMC, and treated with breast-conserving surgery and adjuvant radiation therapy without chemotherapy after two medical oncologists gave opposing recommendations regarding systemic treatment. She has remained without evidence of disease at two-year follow-up. This case adds to the limited literature on FLMC, supports surgery and radiation alone as a potentially effective treatment strategy in carefully selected patients, and highlights the importance of recognizing FLMC as a biologically distinct entity that should not be managed the same way as conventional triple-negative breast cancer, though longer-term follow-up is needed given the limited data on treatment outcomes for this rare tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.